Reify Health
Funding History
| Series C · 08/2021 | $2.2B |
|---|---|
| Series D · 04/2022 | $4.8B |
About
Headquartered at 33 Arch St, Boston, Massachusetts, per business-directory records.
- headquarters
- Boston, Massachusetts
- totalDisclosedFunding
- $477.00M
- latestPostMoneyValuation
- $4.80B (reported, exact figure not disclosed)
- lastRoundSeries
- Series D
- lastFundingDate
- 04/2022
Overview
Reify Health builds software and operational infrastructure used across the clinical-trials industry. Its StudyTeam platform connects sponsors, contract research organizations, and research sites on a shared system intended to make patient enrollment more predictable, while its Care Access unit operates a network of research sites and mobile clinical-trial staff aimed at reaching patients outside traditional academic medical centers.
The company was co-founded by Ralph Passarella, who serves as Chief Executive Officer, and Michael Lin. Reify Health has disclosed four venture rounds between 2018 and 2022, reaching a post-money valuation reported at more than $4.8 billion in its April 2022 Series D round, backed by investors including Coatue Management, Altimeter Capital, ICONIQ Growth, Battery Ventures, Sierra Ventures, and Adams Street Partners.
Private securities are speculative, illiquid, and involve risk of complete loss of principal. You should be prepared to hold private securities for an extended period; there is no assurance of a secondary market, an IPO, or other liquidity event. You are fully responsible for conducting your own due diligence. Pricing is indicative — nothing here is an offer of securities.